Comparison of the effectiveness of Pariet and Rabeprazole-sza
The effectiveness of Pariet is quite similar to Rabeprazole-sz - this means that the ability of the drug substance to provide the maximum possible effect is similar.
For example, if the therapeutic effect of Pariet is more pronounced, then using Rabeprazole-sza even in large doses will not achieve this effect.
Also, the speed of therapy - an indicator of the speed of therapeutic action - is approximately the same for Pariet and Rabeprazole-sza. And bioavailability, that is, the amount of a drug reaching its site of action in the body, is similar. The higher the bioavailability, the less it will be lost during absorption and use by the body.
Comparison of the effectiveness of Losek Maps and Pariet
Pariet is more effective than Losek Mapsa - this means that the ability of the drug substance to provide the maximum possible effect is different.
For example, if the therapeutic effect of Pariet is more pronounced, then it is impossible to achieve this effect with Losek Mapsa even in large doses.
Also, the speed of therapy is an indicator of the speed of therapeutic action; Pariet and Losek maps are also different, as is bioavailability - the amount of a drug substance reaching the place of its action in the body. The higher the bioavailability, the less it will be lost during absorption and use by the body.
Comparison of safety of Pariet and Rabeprazole-sza
The safety of a drug includes many factors.
At the same time, in Pariet it is quite similar to Rabeprazole-sz. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in Pariet, as well as in Rabeprazole-sza, we look at which organ is the metabolizing organ and how critical the effect on it is.
The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Pariet does not have any risks when used, just like Rabeprazole-sza.
Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Pariet and Rabeprazole-sza.
Comparison of safety of Losek maps and Pariet
The safety of a drug includes many factors.
At the same time, it is higher for Pariet than for Losek maps. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in Pariet, as well as in Losek maps, we look at which organ is the metabolizing organ and how critical the effect on it is.
The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Pariet has fewer risks when used than Losek maps.
Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Pariet and Losek maps.
Comparison of addiction between Pariet and Rabeprazole-sza
Like safety, addiction also involves many factors that must be considered when evaluating a drug.
So, the totality of the values of such parameters as “o syndrome” in Pariet is quite similar to the similar values in Rabeprazole-sza. Withdrawal syndrome is a pathological condition that occurs after the cessation of intake of addictive or dependent substances into the body. And resistance is understood as initial immunity to a drug; in this it differs from addiction, when immunity to a drug develops over a certain period of time. The presence of resistance can only be stated if an attempt has been made to increase the dose of the drug to the maximum possible. At the same time, Pariet's syndrome values are quite low, just like Rabeprazole-sza.
Instructions for use PARIET
Antiulcer drug. H+-K+-ATPase (proton pump) inhibitor.
Mechanism of action
Rabeprazole sodium belongs to a class of antisecretory compounds that are chemically substituted benzimidazoles. The drug inhibits the activity of the enzyme H+-K+-ATPase, thereby blocking the final stage of hydrochloric acid synthesis. This effect is dose-dependent and leads to inhibition of both basal and stimulated acid secretion, regardless of the stimulus. As a weak base, rabeprazole in any dose is quickly absorbed and concentrated in the acidic environment of parietal cells.
Antisecretory activity
After oral administration of rabeprazole at a dose of 20 mg, the antisecretory effect occurs within 1 hour and reaches a maximum after 2-4 hours. Inhibition of basal and food-stimulated acid secretion 23 hours after taking the first dose of rabeprazole sodium was 62 and 82%, respectively, and the duration of this the effect reached 48 hours. The inhibitory effect of rabeprazole sodium on acid secretion increases slightly with daily intake of 1 tablet, stable inhibition of secretion is achieved 3 days after starting the drug. After stopping taking rabeprazole, secretory activity is restored after 2-3 days.
The role of Helicobacter pylori in the development of peptic ulcers, including gastric ulcers and duodenal ulcers, has been noted. Helicobacter pylori is a major factor in the development of gastritis and ulcers in such patients. Recent studies suggest a causal relationship between Helicobacter pylori and gastric carcinoma.
In vitro, rabeprazole was found to have a bactericidal effect against Helicobacter pylori. Eradication of Helicobacter pylori with Pariet and antimicrobial drugs leads to a high degree of healing of mucosal lesions. Based on the results of controlled randomized clinical trials, it was found that taking rabeprazole 20 mg 2 times a day in combination with two antibiotics, for example, clarithromycin and amoxicillin or clarithromycin and metronidazole for 1 week, can achieve a Helicobacter pylori eradication rate of more than 80% in patients with gastroduodenal ulcers. As expected, a trend toward lower eradication rates was observed in patients with underlying metronidazole resistance. When choosing an appropriate combination for Helicobacter pylori eradication, one should be guided by approved treatment standards. In patients with persistent infection (in the presence of initially sensitive strains of microorganisms), it is necessary to take into account the possibility of developing secondary resistance to antibacterial drugs when choosing a treatment regimen.
Effect on serum gastrin concentrations
During clinical trials, patients took 10 mg or 20 mg of rabeprazole once a day for a treatment duration of up to 43 months. During the first 2-8 weeks of therapy, serum gastrin concentrations increased, reflecting an inhibitory effect on acid secretion. Gastrin concentrations returned to baseline levels usually within 1-2 weeks after cessation of treatment.
A study of biopsies of the fundus and antrum of the stomach in more than 500 patients treated with rabeprazole for up to 8 weeks did not reveal changes in the histology of enterochromaffin-like cells, the severity of gastritis, the incidence of atrophic gastritis, intestinal metaplasia and the prevalence of Helicobacter pylori infection. In a study of 250 patients taking rabeprazole for 36 months, no significant deviations from the baseline were found.
Other effects
There is currently no evidence that rabeprazole causes systemic effects on the central nervous system, cardiovascular and respiratory systems. Rabeprazole, when taken orally at a dose of 20 mg/day for 2 weeks, had no effect on thyroid function, carbohydrate metabolism, as well as on blood concentrations of parathyroid hormone, cortisol, estrogen, testosterone, prolactin, cholecystokinin, secretin, glucagon, FSH, LH, renin, aldosterone and growth hormone.
Comparison of side effects of Pariet and Rabeprazole-sza
Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.
Pariet has almost the same level of adverse events as Rabeprazole-sza. They both have few side effects. This implies that the frequency of their occurrence is low, that is, the indicator of how many cases of an undesirable effect of treatment are possible and registered is low. The undesirable effect on the body, the strength of influence and the toxic effect of Pariet are similar to Rabeprazole-sz: how quickly the body recovers after taking it and whether it recovers at all.
Comparison of side effects of Losec Maps and Pariet
Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.
Losek Mapsa has almost the same level of adverse events as Pariet. They both have few side effects. This implies that the frequency of their occurrence is low, that is, the indicator of how many cases of an undesirable effect of treatment are possible and registered is low. The undesirable effect on the body, the strength of influence and the toxic effect of Losek maps are similar to Pariet: how quickly the body recovers after taking it and whether it recovers at all.
Comparison of ease of use of Pariet and Rabeprazole-sza
This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.
The ease of use of Pariet is approximately the same as Rabeprazole-sz. However, they are not convenient enough to use.
The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.
Last update date: 2020-12-13 10:32:07
Comparison of ease of use of Losek mapsa and Pariet
This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.
The ease of use of Losek Mapsa is approximately the same as Pariet. However, they are not convenient enough to use.
The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.
Last update date: 2020-12-04 13:43:42
Comparison of the effectiveness of Dexilant and Pariet
The effectiveness of Dexilant is quite similar to Pariet - this means that the ability of the drug substance to provide the maximum possible effect is similar.
For example, if the therapeutic effect of Dexilant is more pronounced, then using Pariet even in large doses will not achieve this effect.
Also, the speed of therapy - an indicator of the speed of therapeutic action - is approximately the same for Dexilant and Pariet. And bioavailability, that is, the amount of a drug reaching its site of action in the body, is similar. The higher the bioavailability, the less it will be lost during absorption and use by the body.
Comparison of safety of Hairabezol and Pariet
The safety of a drug includes many factors.
At the same time, in Khairabezol it is quite similar to Pariet. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in Khairabezol, as well as in Pariet, we look at which organ is the metabolizing organ and how critical the effect on it is.
The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, Hairabezol does not have any risks when used, just like Pariet.
Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using Khairabezol and Pariet.
Comparison of side effects of Dexilant and Pariet
Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.
Dexilant has more side effects than Pariet. This implies that the frequency of their occurrence is low in Dexilant and low in Pariet. Frequency of occurrence is an indicator of how many cases of an undesirable effect from treatment are possible and registered. The undesirable effect on the body, the strength of influence and the toxic effect of drugs are different: how quickly the body recovers after taking it and whether it recovers at all. When using Dexilant, the body's ability to recover faster is higher than that of Pariet.
Comparison of the effectiveness of Hairabezol and Pariet
Pariet is more effective than Hairabezol - this means that the ability of the drug substance to provide the maximum possible effect is different.
For example, if the therapeutic effect of Pariet is more pronounced, then with Hairabezol it is impossible to achieve this effect even in large doses.
Also, the speed of therapy is an indicator of the speed of the therapeutic action; Pariet and Hairabezol are also different, as is bioavailability - the amount of a drug substance reaching the place of its action in the body. The higher the bioavailability, the less it will be lost during absorption and use by the body.
